TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven breast, head and neck, prostate, or cervical carcinoma or high grade (defined as grades 2 or 3) soft tissue sarcoma Sarcoma tumors must be confined to truncal or extremity locations Must have a clinical condition and physiologic status which demonstrates that the appropriate or standard initial therapy for the tumor is surgical biopsy or resection Tumors no greater than 15 cm in any diameter Hormone receptor status: Not specified~PATIENT CHARACTERISTICS: Age: 18 and over Menopausal status: Not specified Performance status: ECOG 0 or 1 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count greater than 2,000/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin less than 2.0 mg/dL Renal: Creatinine less than 2.0 mg/dL OR Creatinine clearance greater than 50 mL/min Cardiovascular: No significant cardiac disease that would preclude the safe use of general anesthesia Pulmonary: No significant pulmonary disease that would preclude the safe use of general anesthesia Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 1 month after study No grade 3 or 4 peripheral neuropathy~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A proven diagnosis of one of the conditions in Table 1.~* Prior therapy including blood or marrow transplant will not exclude patients for reduced intensity transplant.~* Age \< 75 years. Pediatric patients are eligible from the ages of 1 month to 18 years if the transplant physician believes that co-morbid conditions significantly increase the risk for a standard transplant regimen.~* HIV antibody negative.~* ECOG performance status 0-3, (or equivalent Karnofsky and Lansky performance scores for patients \<18yrs, see appendix 2)~* Availability of an HLA-identical related donor or suitable alternative donor, (≥7/8 allele match at A, B, C and DRB). Syngeneic transplants will not be allowed in this protocol.~* Due to the complexity of the study, all patients prior to enrollment will be assessed by the PI or co-PI.~* Patient with marrow failure states or immune deficiency syndromes undergoing stem cell transplants must be reviewed by one of the investigators to determine eligibility for study.~* Adequate insurance coverage (or financial resources) to cover the costs associated with the patient's transplant and, in the case of patients eligible for cohort C, to cover the costs associated with I 131 Tositumomab treatment.~Exclusion Criteria:~* Active CNS involvement with malignant disease.~* Pregnancy.~* Fertile men or women unwilling to use contraceptive techniques during the study period.~* Creatinine clearance \< 30 ml/min.~* Left ventricular ejection fraction \<30% or clinical cardiac failure uncontrolled by medical therapy.~* Pulmonary disease requiring supplemental oxygen therapy.~* Patients with estimated life span less than 1 year due to medical illnesses other than the condition being treated on the study.~Donor Selection:~Inclusion Criteria~* Major HLA identical relative or genotypically matched unrelated donor (7-8/8 alleles) .~* Donors must meet the selection criteria as defined by the Foundation for the Accreditation of Cell Therapy (FACT) and will be screened per the American Association of Blood Banks (AABB) guidelines.~Exclusion Criterion~* Positive anti-donor HLA antibody.~* Identical twin.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm, non-randomized study (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients who answer TRUE to the following criteria may be eligible to participate in this study.~* Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has NOT spread to the other parts of the body (metastases). Patients with lymph node involvement may be eligible if specified criteria is met.~* Increasing Prostate Specific Antigen (PSA), collected within one year of enrollment~* Currently receiving treatment with surgical or medical castration~Exclusion Criteria:~Patients who answer TRUE to the following may NOT be eligible to participate in this study.~* Currently using opiate based pain killers for cancer related pain~* Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone). Prior targeted cancer therapies are permitted if received during a previous clinical trial~* Suffering from heart failure or had a myocardial infarction within last 6 months~* A history of epilepsy or seizures

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo
- ZD4054 (Type: EXPERIMENTAL): ZD4054 (Zibotentan)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Timolol Eye Drops in the Treatment of Acute Migraine Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of migraine headache~Exclusion Criteria~* Non-migraine headache~* Use of systemic beta-blocker~* Medical history of hypotension, bradycardia, syncope or other significant cardiovascular disease~* Medical history of difficulty breathing, asthma or chronic obstructive pulmonary disease or other pulmonary disease~* Medical history of glaucoma, ocular hypertension or hypotony, punctual stenosis, current use of other ophthalmic medications~* Previous adverse reaction to timolol or other beta-blockers~* Inability to self-administer eye drop due to physical or cognitive disorders~* Currently pregnant or breastfeeding~* Pregnant in the past year~* Non-english speaker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Timolol eye drops (Type: ACTIVE_COMPARATOR): All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.
- Artificial tears (Type: PLACEBO_COMPARATOR): All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: BACTERIA ISOLATION FROM STOOLS COLLECTED FROM CENTENARIANS PEOPLE

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 95 years and older~* BMI between 18.5 and 25 kg/m2~* Clinical exam normal~* Subject agreeing to participate in the study and not objecting to participate in the study.~* Able and willing to provide samples of blood and faeces~Exclusion Criteria:~* Diagnosed acute or chronic gastrointestinal disease or complication (e.g., celiac disease, gastroesophageal reflux, gastric or duodenal ulcer, Crohn's disease, hemorrhoids, irritable bowel syndrome)~* Infectious gastrointestinal event within 3 months prior to inclusion~* Diabetes~* Severe chronic disease (active cancer, HIV, severe renal failure, ongoing severe heart or liver or biliary disorders, arthritis) or severe chronic disease deemed incompatible with the conduct of the study by the investigator~* Major surgical procedure likely to disrupt the intestinal microbiota, within 6 months prior to inclusion~* Recent food allergy \< 3 months prior to inclusion~* Antibiotic, antiviral, antifungal, proton pump inhibitor or any other treatment likely to disrupt the microbiota in the 3 months prior to inclusion~* Previous or current use of a treatment that may disrupt the microbiota (e.g. laxatives, antidiarrheals, antacids...) in the last 3 months~* Significant change in dietary habits or physical activities in the 3 months prior to inclusion~* Consumption of more than 2 standard glasses of alcoholic beverages per day~* Smoking \> 20 cigarettes per day, illicit drug use,~* Daily use of non-steroidal anti-inflammatory drugs (NSAIDs)~* Severe psychiatric or neurological pathology~* Completely dependent subject (GIR Score = 1)~* Subject with liquid stools (Bristol Score = 7) or very hard stools (Bristol Score = 1)~* Vaccination in the last month before inclusion~* Subject unable to understand the purpose of the research, answer questions and give their decision to participate in the study~* Subject already included in another research study involving the human subject~* Subject under guardianship and whose guardianship objects to the participation of his/her protectee,~* Subject not affiliated with a social security plan or not a beneficiary of such a plan

- Gender: FEMALE
- Minimum Age: 95 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Centenarian cohort (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with CML in chronic phase (patients already on imatinib)~* Presence of Philadelphia chromosome or bcr-abl rearrangement~* Age ≥ 18 years~* ECOG performance status ≤ 2~* Written informed consent~Exclusion Criteria:~* Hepatic dysfunction (serum bilirubin ≥ 2 x ULN, and/or ALT ≥ 3 x ULN, and/or AST ≥ 3 x ULN)~* Renal dysfunction (creatinine ≥ 200 μmol/l or 2.3 mg/dl)~* Severe cardiac dysfunction (NYHA classification III-IV)~* Severe pulmonary or neurologic disease~* Pregnant or lactating females~* Patients with a history of active malignancy during the past 5 years with the exception of nonmetastatic skin cancer (e.g. treated squamous or basal cell carcinoma) or stage 0 cervical carcinoma~* Patients known to be HIV-positive~* Patients with active, uncontrolled infections~* Male and female patients of reproductive potential who are not practicing effective means of contraception~* Patients with known allergic reaction or intolerance to either imatinib or zileuton~* Patients requiring anticoagulation therapy with coumadin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- single arm of experimental drug combination (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Self-Propelled Percutaneous Endoscopic GastroJejunostomy (PEG-J)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age 18-90 years~* need for post-pyloric feeding (patients unable to eat due to stroke, intubated patients with respiratory failure, patients with acute pancreatitis, etc)~* ability to give informed consent for the study~Exclusion Criteria:~* patients with uncorrectable bleeding disorders (INR more than 1.5, platelet count less than 50,000)~* inability to get informed consent for the study from patients or their families~* pregnancy (all women of child-bearing age will undergo urine pregnancy testing)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- PEGJ (Type: EXPERIMENTAL): Patients in this arm will receive self-propelled balloon PEGJ tube.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radiofrequency Ablation for Amiodarone-induced Thyrotoxicosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Are adults~* Have overt thyrotoxicosis (within 2 weeks prior to enrollment)~* Are receiving medical therapy for AIT~* Are able to understand the study procedures and to comply with them for the entire length of the study~* Have not normalized their thyroid levels after one month of standard therapy or~* Have persistent and clinically significant thyrotoxicosis (less than 25% decrease in T4 value or patients requiring hospitalization with Congestive heart failure (CHF), tachyarrhythmias, hemodynamic instability or similar co-morbidities) after 2 weeks of standard therapy where additional medical therapy is deemed unlikely to be beneficial or with high risk of side-effects (e.g. hepatotoxicity of antithyroid medications, agranulocytosis of potassium perchlorate or ATD or fluid retention associated with steroids).~Exclusion Criteria:~* Pregnancy~* Patients with prior neck surgery or neck radiation~* Patients with neck anatomy that precludes easy access by RFA to the entirety of thyroid parenchyma~* Patients on anticoagulation therapy~* Patients with comorbidities deemed too high of a risk for general anesthesia~* Treatment with another investigational drug or intervention (within 6 weeks of planned RFA).~* Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.~* Inability or unwillingness of individual or legal guardian/representative to give written informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RFA group (Type: EXPERIMENTAL): RFA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18 years old~* ECOG performance status 0-2~* Non-squamous cell type non-small cell lung cancer (NSCLC)~* Stage IV, Stage IIIB cannot be treated with curative intent or Relapsed after surgery or radiation therapy~* No prior chemotherapy except adjuvant chemotherapy and concurrent chemoradiation treatment. The last dose of adjuvant chemotherapy should be at least 6 months earlier from randomization, and the regimen should not contain docetaxel or pemetrexed.~* No prior immunotherapy, biologic therapy~* Measurable lesion with Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1~* Hemoglobin \>=9.0g/dl, Platelet \>=100,000/uL, neutrophil \>=1,500 /uL Creatinine \<=1.5 x upper normal limit or creatinine clearance \>=60 mL/min Bilirubin \<=1.5 x upper normal limit, Transaminases \<=2 x upper normal limit Alkaline phosphatase \<=2 x upper normal limit~* Written informed consent~Exclusion Criteria:~* Pregnancy, Lactating woman~* Woman in child bearing age who refuses to do pregnancy test~* Moderate or greater than grade 1 motor or sensory neurotoxicity~* Hypersensitivity to taxane~* Comorbidity or poor medical conditions~* Other malignancy (except cured basal cell carcinoma or uterine cervical carcinoma in situ)~* Concurrent treatment with other investigational drugs within 30 days before randomization~* Active treatment with other anticancer chemotherapy~* EGFR mutation (exon 19 deletion, L858R, L861Q, G719A/C/S)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Taxotere (Type: EXPERIMENTAL): Docetaxel plus Cisplatin
- Pemetrexed (Type: ACTIVE_COMPARATOR): Pemetrexed plus Cisplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1-infected patients with no previous AIDS event (excluding a healed tuberculosis);~* Current antiretroviral treatment associating dolutegravir + abacavir + lamivudine for at least 1 month;~* Nadir CD4 ≥ 100/mm3;~* Plasma RNA viral load \< 50 copies/ml for at least 12 months;~* Plasma RNA viral load \<20 or 40 copies/ml (according to the threshold of the method used by local laboratory) at the screening visit;~* No documented virologic failure or known resistance to any integrase inhibitor,~* Patient having provided a written consent;~* Patients follow-up possible in ambulatory;~* Patient age \> 18 years;~* Covered by health insurance~Exclusion Criteria:~* Non-compliant patient~  * Subject is pregnant, or lactating, or of childbearing potential and without contraception;~ * Active opportunistic infections (defining AIDS);~ * Known hypersensibility to abacavir or lamivudine or dolutegravir;~ * Patients harboring HLA B\*5701;~ * Major overweight (BMI ≥ 40);~ * Weight \<40 kg;~ * Creatinine clearance \< 50ml/min;~ * Cirrhosis or severe liver failure (factor V \< 50%);~ * Life Prognosis threatened within 6 months;~ * Circumstances that may impair judgment or understanding of the information given to the patient;~ * Co-medication with carbamazepin, oxcarbamazepin, fosphenytoïn, phenobarbital, phenytoïn, primidon, St John's wort or dofetilid;~ * Malabsorption syndromes;~ * The following laboratory criteria:~    * Serum AST,ALT \> 5 x upper limit of normal (ULN)~   * Thrombocytopenia with platelet count \< 50.000/ml~   * Anemia with hemoglobin \< 8g/dl~   * Polynuclear neutrophil count \< 500/mm3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- triple therapy (Type: ACTIVE_COMPARATOR): dolutegravir + abacavir + lamivudine (TRIUMEQ) : oral administration, one tablet daily during 48 weeks.
- monotherapy (Type: EXPERIMENTAL): dolutegravir (TIVICAY) : 50 mg, oral administration, one tablet daily during 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Real Life Safety and Efficacy of Vardenafil

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Any adult patient (\>/=18 years) with erectile dysfunction treated with LEVITRA®.~* Patients must be able to give written informed consent for participation in the study after receiving detailed written and oral information prior to the study.~Exclusion Criteria:~* Exclusion criteria must be read in conjunction with the product information (Package Insert).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Panitumumab and Radiotherapy in Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ECOG Performance Status 0-1~* Histologically proven adenocarcinoma of the rectum, T3-T4 and/or N+ M0~* Wild-type KRAS~* No prior pelvic irradiation~* Normal bone marrow, hepatic, renal, cardiac functions~* No secondary malignancy~* No other active, uncontrolled disease~* Signed informed consent~Exclusion Criteria:~* KRAS mutation~* Established or suspected metastasis~* Prior pelvic irradiation~* Previous exposure to EGFR-targeting therapies~* Patients under any other investigational agent(s)~* Concurrent systemic immune therapy, chemotherapy, hormone therapy~* Drug and/or alcohol abuse~* Grade 3 to 4 allergic reaction to any of the components of the treatment~* History or presence of interstitial lung disease~* Active, uncontrolled cardiovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- panitumumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy